Clinical Trial Finder

• Restore CFTR FunctionEnrolling

  Study to evaluate VX-561 in adults 18 years and older with cystic fibrosis , protocol number Vertex VX-561-101

  This study will look at the safety and effectiveness of the drug VX-561, a drug intended to help CFTR function closer to normal.

  • Age:

    18 Years and Older

  • Mutation(s):

    One Copy F508del or No Copies F508del

  • FEV1% Predicted:

    40 to 100%

  • Number of Visits:

    8

  • Length of Participation:

    16 weeks

• Mucociliary ClearanceEnrolling

  SHIP CT: Study of hypertonic saline in preschoolers , protocol number SHIP002

  This study is taking place in Europe, Australia and the U.S. It will look at the safety and effectiveness of hypertonic saline compared to isotonic saline (normal saline) in children with CF.

  • Age:

    3 Years to 5 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    6

  • Length of Participation:

    54 weeks

• Anti-InflammatoryEnrolling

  Phase 2 study of lenabasum in people with CF ages 12 and older , protocol number Corbus JBT101-CF-002

  This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the potential anti-inflammatory drug lenabasum and will use a placebo control.

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40 to 100%

  • Number of Visits:

    10

  • Length of Participation:

    32 weeks

• Anti-InfectiveEnrolling

  Phase 3 study of inhaled vancomycin in adults and children 6 years and older with cystic fibrosis , protocol number Savara SAV005-04

  This study is taking place at multiple care centers across the U.S. It will look at the effectiveness of the inhaled drug vancomycin in adults and children 6 years and older with cystic fibrosis and positive cultures for methicillin-resistant Staphylococcus aureus (MRSA).

  • Age:

    6 Years to 21 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    30 to 90%

  • Number of Visits:

    13

  • Length of Participation:

    12 months

• ObservationalEnrolling

  Study to evaluate the effects of the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor (PROMISE) , protocol number PROMISE-OB-18

  This observational study will measure the effects of the triple-combination therapy, elexacaftor/tezacaftor/ivacaftor, in people with CF. These drugs are intended to help CFTR protein function closer to normal. This study will look at how treatment with the triple-combination therapy affects people with CF across many different aspects of the disease.

  • Age:

    12 Years and Older

  • Mutation(s):

    Two Copies F508del or One Copy F508del

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    6

  • Length of Participation:

    2 years

• OtherEnrolling

  Study of SPI-1005 in people with CF ages 18 and older , protocol number Sound Pharma SPI-3005-501.2

  This study will test the safety and tolerability of SPI-1005, a drug intended to prevent and treat hearing loss caused by aminoglycosides.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    40% or greater

  • Number of Visits:

    6

  • Length of Participation:

    49 days

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.